Italia markets closed

Laboratorios Farmaceuticos Rovi, S.A. (0ILL.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
39,33-0,21 (-0,54%)
Alla chiusura: 06:45PM GMT

Laboratorios Farmaceuticos Rovi, S.A.

Calle José Isbert, 2
Pozuelo de Alarcón
Madrid 28223
34 91 021 30 00

Impiegati a tempo pieno1.751

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Juan Lopez-Belmonte EncinaPres, CEO & Director1,74MN/DN/D
Mr. Ivan Lopez-Belmonte EncinaSecond Deputy Chairman & Head of Corp. Devel.1,51MN/DN/D
Mr. Javier Lopez-Belmonte EncinaFirst Deputy Chairman & CFO1,51MN/DN/D
Ms. Mercedes Benítez del Castillo SánchezLegal Department Mang.N/DN/DN/D
Mr. Fernando Martínez MoralesDirector of SalesN/DN/DN/D
Ms. Rosario Perucha PérezMarketing Mang.N/DN/DN/D
Mr. Francisco Javier Angulo GarcíaHR Mang.N/DN/DN/D
Mr. Gabriel Nunez FernandezSec.N/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2021 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.


Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company distributes other products that are licensed from other laboratories. Its principal products include Hibor, a low-molecular-weight heparin to prevent and treat venous thromboembolic disease; Enoxaparin biosimilar Becat, a low-molecular-weight heparin; Neparvis to treat symptomatic chronic heart failure with reduced ejection in adult patients; Absorcol, Vytorin, and Orvatez to diet in patients with hypercholesterolemia; Hirobriz Breezhaler and Ulunar Breezhaler that are long-acting bronchodilators for the maintenance treatment of chronic obstructive pulmonary diseases; Volutsa for treatment of moderate to severe storage systems symptoms and voiding symptoms associated with benign prostatic hyperplasia in men who are not responding adequately to monotherapy treatment; and Medikinet and Medicebrán to treat attention deficit hyperactivity disorder in children and teenagers. The company also markets various hospital products for imaging diagnosis, such as Iomeron and Iopamiro for computed tomography and intervention; Multihance and Prohance for magnetic resonance imaging; Sonovue for ultrasounds; and EmpowerCTA+, EmpowerMR, and CT Exprès that are contrast injection systems and compatible disposable material. It provides non-prescription pharmaceutical products; and contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, hard capsules, and sachets. The company serves wholesalers, doctors, nursing staff, pharmacists, and patients. It has a collaboration with Moderna, Inc. for manufacturing mRNA COVID-19 vaccine candidate. The company was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.

Governance aziendale

L'ISS Governance QualityScore di Laboratorios Farmaceuticos Rovi, S.A. al 1 febbraio 2023 è 3. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 5; diritti degli azionisti: 6; retribuzione: 3.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.